Manufacturing

Preventative maintenance of heat transfer fluid systems is important for reducing downtime in pharmaceutical manufacturing.

The company has passed inspection by the UK Medicines and Healthcare products Regulatory Agency, and is now licensed to develop, manufacture, and pack non-potent and potent solid oral drug products at its site in Loughborough, England.

As part of the $900-million deal, Incyte will pay $150 million upfront to develop and commercialize an anti-PD-1 drug candidate from biopharmaceutical company, MacroGenics.

AbbVie will pay a $205-million upfront payment and have the option to develop and commercialize two antibody targets globally.

The company has opened new facilities and an innovation center in Singapore, China that will focus on the development of plant-based products.

The M&A advisory firm has developed an interactive map of manufacturing sites to give insight into the market size of global manufacturing.

ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility.

The biopharmaceutical company has received a $4.2-million grant from the Bill & Melinda Gates Foundation to invest in the development of new treatments for Enterotoxigenic Escherichia coli infections, a bacterial cause of diarrhea in the developing world.

The API manufacturer has announced that it has completed the expansion of large-scale manufacturing capabilities at its Charles City, Iowa site.

The company is recalling several injectable products because of possible microbial contamination.

The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.

The clinical-stage biopharmaceutical company has announced the opening of a new gene therapy manufacturing facility in Modiin, Israel, which is anticipated to be the production site of the company’s lead cancer drug candidate.

The biotechnology company has officially opened its new Michigan research and production center for the production of spider silk-based fibers, as well as for the company’s polymer research and development program.

This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.

The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.

SCHOTT began production of glass ampoules, vials, and cartridges at a new facility at the SCHOTT Xinkang headquarters in Zhejiang, China.

The company has announced that it has acquired a new bioanalysis and biomarkers services facility in Laval, Montreal, Canada to support preclinical and clinical programs.

How soon could the pharmaceutical industry see a widespread adoption of emerging technologies that are poised to shape its future?

Rutgers University-based C-SOPS annual meeting described advances in continuous manufacturing understanding and future plans for broader education efforts.

The two companies announced their collaboration for the production and development of cancer vaccines.

Water shortages, testing expenses, and effluent treatment are important issues for pharma manufacturers.

Gerresheimer is showcasing its range of Duma Pocket containers, which are available in different sizes and colors and come with various closures.

The partnership and the formation of the institute intend to bring together industry, academia, and regulators to tackle challenges and provide solutions for continuous manufacturing.

Most pharma supply chain partners believe that manufacturers should pay for blockchain implementations, and own the data.

Almac Group’s Almac Pod, a temperature-controlled shipping solution service for biologics and other temperature-sensitive products, is available in the United States.

Gerresheimer’s ready-to-fill vials will be delivered adopting Ompi EZ-fill packaging process.

The companies will collaborate to produce and improve the recombinant properties of Aethlon’s Hemopurifier blood purification device.

The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.

The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.

Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity.